Polymicrobial Infection in Mice
|
|
- Bryce Gardner
- 6 years ago
- Views:
Transcription
1 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUlY 1993, P /93/ $02.00/0 Copyright 1993, American Society for Microbiology Vol. 37, No. 7 Use of Cephalosporins for Prophylaxis and Therapy of Polymicrobial Infection in Mice ITZHAK BROOK Naval Medical Research Institute, Bethesda, Maryland Received 29 January 1993/Accepted 28 April 1993 Cefoxitin, cefotetan, and cefmetazole were compared in 10-day therapy of intra-abdominal and subcutaneous infections caused by three organisms: Bacteroidesfragilis and Bacteroides thetaiotaomicron combined with either Escherichia colt or Staphylococcus aureus. Intra-abdominal infection was caused by B. fragilis plus B. thetaiotaomicron plus E. coil. Therapy was initiated immediately before inoculation or was delayed for 8 h. Mortality was 14 of 30 (47%) for saline-treated mice, and all survivors developed abscesses. Immediate therapy reduced mortality and the percentage of mice with abscesses (in survivors), respectively, to 17 and 20%o with cefoxitin, 0 and 13% with cefotetan, and 0 and 17% with cefmetazole, and the numbers of all bacteria were reduced by all the cephalosporins. Delayed therapy reduced mortality and abscess formation, respectively, to 20 and 8% of mice with cefoxitin, 10 and 93% with cefotetan, and 7 and 96% with cefmetazole. B. thetaiotaomicron survived in all abscesses treated with cefotetan and cefmetazole. Subcutaneous abscesses were caused by each organism alone or in combinations of one aerobe (S. aureus or E. coli) and one or two Bactetoides species. Early therapy reduced the numbers of all bacteria independent of their in vitro susceptibility. All agents reduced the number of each Bacteroides species with either E. coli or S. aureus. However, when therapy was delayed, cefotetan and cefmetazole were less effective than cefoxitin against B. thetaiotaomicron. Cefotetan was the most active agent against E. coli, and cefmetazole was the most effective against S. aureus. These data illustrate the efficacy of all tested cephalosporins in the prophylaxis of polymicrobial infections. Bacteroides fragilis group organisms mixed with Escherichia coli are frequently isolated from intra-abdominal (i.a.) infections that originate from the gut flora (5, 15). These organisms mixed with Staphylococcus aureus are often recovered from skin and soft tissue infections around rectalvulvovaginal and oral areas (8). The B. fragilis group consists of several subspecies that were elevated to full species level (11). The rates of recovery of the different species of the B. fragilis group differ for various infection sites. The distribution ofb. fragilis group species can affect the management of these infections because of the different antimicrobial susceptibilities of the various group members. B. fragilis group organisms produce a potent cephalosporinase, and their susceptibilities to expanded- and broad-spectrum cephalosporins are not uniform (1). B. fragilis is the most susceptible, while Bacteroides thetaiotaomicron and other B. fragilis group members are more resistant (1, 12, 14). The purpose of this study was to evaluate several expanded-spectrum cephalosporins advocated as single-agent therapy for the prophylaxis and management of polymicrobial infections. Their abilities to prevent and treat mixed infections caused by two members of the B. fragilis group and either E. coli or S. aureus were tested in i.a. and subcutaneous (s.c.) abscess models in mice. In contrast to previous studies in which combinations of two isolates (a B. fragilis isolate plus E. coli or S. aureus) were used, this study employed inoculation of three organisms, which more truly simulates the polymicrobial infection that occurs in patients. (This study was presented in part at the First North American Congress on Anaerobic Bacteria and Anaerobic Infections, Marina Del Ray, Calif., 25 July 1992.) 1531 MATERIALS AND METHODS The experiments reported herein were conducted according to the principles set forth in Guide for the Care and Use of Laboratory Animals (1Sa). Organisms. All aerobic and anaerobic bacteria used in the experiments were recent clinical isolates. These included one isolate each of B. fragilis (NMRI isolate 32), B. thetaiotaomicron (NMRI isolate 54), E. coli (NMRI isolate 8), and S. aureus (NMRI isolate 7). The bacteria were kept frozen in skim milk at -70 C. They were identified by standard criteria (18, 22) and processed as previously described (10). All Bacteroides species were encapsulated (>50% of the organisms had capsules). The encapsulated form was induced by passage of the nonencapsulated form mixed with Kebsiella pneumoniae in s.c. abscesses in mice (17). The presumptive identification of a capsule was established by microscopic examinations only, by electron microscopy after staining with ruthenium red (17), which demonstrated a homogeneous polysaccharide capsule that was external to the cell wall. Bacterial suspensions of organisms for inoculation were prepared as previously described (7). Numbers of CFU were determined by plate count with brain heart infusion agar enriched with vitamin K1 and hemin to support the growth of the Bacteroides species. Animals. Male Swiss albino mice weighing 20 to 25 g each were obtained from the Institute's mouse colony. The mice were raised under conventional conditions. Abscess induction. Abscesses were induced as previously described (10). For induction of i.a. abscesses, mice received intraperitoneally a mixture of 0.1 ml of each bacterial suspension in saline (containing 103 live E. coli cells and 105 live cells of each of the two B. fragilis group isolates) and
2 1532 BROOK 0.05 ml of sterile human fecal adjuvant solution (total volume, 0.35 ml). For induction of s.c. abscesses, mice were inoculated s.c. in the right groin with 0.1 ml of each appropriate bacterial suspension in saline solution containing 10 of each organism. Cultivation of abscesses. (i) i.a. abscesses. Ten days after abscess induction, the mice were killed by cervical dislocation. For each mouse, the abdomen was sterilely prepared, and a t-shaped incision was used to thoroughly explore the abdomen and pelvis. All i.a. abscesses >2 mm in diameter were excised, placed in prereduced saline, and weighed together for each mouse. (ii) s.c. abscesses. Mice were killed 5 days after inoculation, and the s.c. abscess material was aseptically removed. The number of bacteria in each abscess was determined individually. Quantitation of bacteria. Both i.a. and s.c. abscesses were minced, and the homogenate was serially diluted and quantitatively plated aerobically on McConkey's and blood agars and anaerobically on brain heart infusion-enriched blood agar plates. Selective media containing cefotetan were used to quantitatively determine the numbers of the two phenotypically similar Bacteroides species. Growth was evaluated 24 and 48 h after plating. No attempt was made to inactivate the antimicrobial agents in the homogenized abscess material, since a considerable dilution was achieved before plating. Colonies were counted after incubation at 37 C in an anaerobic chamber for 48 h, and the results were presented as log1o of the viable bacteria per peritoneal cavity (for i.a. abscesses) or per abscess (for s.c. abscesses). The lowest detectable number of organisms per 1 ml of pus was 10. This number was used as a zero value for statistical analysis. Antimicrobial therapy. Doses of antimicrobial agents were selected on the basis of pharmacokinetic studies of uninfected animals. Levels of the antibiotics in serum were measured by agar diffusion assay (18) with Bacillus subtilis ATCC at 30, 60, 120, and 180 min and at 8 and 12 h after administration of the last dose of antibiotics. Antimicrobial therapy was started in half of the mice 1 h before inoculation of bacteria and in the other half 8 h after bacterial inoculation. The daily doses of cephalosporins were given intramuscularly, diluted in 0.1 ml of saline, in divided doses every 12 h. The control group received 0.1 ml of saline in divided doses every 12 h. The antimicrobial agents used were cefmetazole (Upjohn Company, Kalamazoo, Mich.), cefoxitin (Merck Sharp & Dohme, West Point, Pa.), and cefotetan (Stuart Pharmaceuticals, Wilmington, Del.). Susceptibility tests. The MICs of the test antibiotics against the bacterial isolates were determined by the agar dilution method (18, 22). Experimental design. To determine the effects of prophylactic and therapeutic use of the cephalosporins on the various organisms in i.a. mixed infections, E. coli was inoculated in combination with the two B. fragilis group members. To determine the effect of therapy on s.c. infection, E. coli and S. aureus were inoculated alone or in combination with one or both B. fragilis group isolates. Therefore, in the first set of i.a. abscess experiments, single organisms were inoculated; in the second set of experiments, two organisms were inoculated (E. coli or S. aureus and one of the two Bacteroides species); and in the third set of experiments, three organisms were injected (E. coli or S. aureus and both of the Bacteroides species). Groups of 10 mice were treated with saline or with one of ANTIMICROB. AGENTS CHEMOTHER. TABLE 1. In vitro susceptibilities of organisms (Og/ml) MIC Cefoxitin Cefotetan Cefmetazole B. fragilis B. thetaiotaomicron E. coli S. aureus the three antimicrobial agents. Each i.a. experiment was done three times, and each s.c. experiment was done twice. Statistical analysis was done by using Student's t test of independent means and the chi-square test. RESULTS In vitro susceptibility to antibiotics. B. fragilis was susceptible to cefoxitin, cefotetan, and cefmetazole, but B. thetaiotaomicron was resistant to the last two. E. coli and S. aureus were susceptible to all agents (Table 1). Antibiotic concentrations in serum. The concentrations of antimicrobial agents in uninfected animals were determined. The peak concentrations in serum were at least four times higher than the MICs for all susceptible bacteria (Table 2). Mortality. Mortality occurred within the first 5 days after inoculation. After i.a. inoculation, mortality in control animals was 47% (14 of 30 mice) (Table 3). Mortality in animals starting to receive cephalosporins prior to inoculation was 17% for cefoxitin and 0% for cefotetan and cefmetazole. Mortality in those receiving cephalosporins 8 h after inoculation was 20% for cefoxitin, 10% for cefotetan, and 7% for cefmetazole (P < 0.05 compared with value for control). No mortality was noted after s.c. inoculation. i.a. infection caused by E. coli with B. fragilis and B. thetaiotaomicron (Table 3). Abscesses were observed in all 16 surviving saline-treated mice. In the mice that started to receive cephalosporins 1 h prior to inoculation, mortality and abscess formation (in survivors) were reduced, respectively, to 17 and 20% with cefoxitin, 0 and 13% with cefotetan, and 0 and 17% with cefmetazole. All three cephalosporins significantly reduced the number of E. coli, B. fragilis, and B. thetaiotaomicron organisms in the abscesses. In the mice whose therapy was started 8 h after inoculation, cefoxitin therapy had effects similar to those it had when therapy was started prior to inoculation. Cefotetan and cefmetazole reduced mortality, but abscesses, mostly due to B. thetaiotaomicron, were noted on 93 and 96%, respectively, of the surviving mice. s.c. abscesses. (i) Abscesses caused by single organisms. s.c. abscesses were induced by each of the four organisms, and the CFU of the organisms in saline-treated mice varied from TABLE 2. Antimicrobial agenta Concentrations of cephalosporins in serum in uninfected mice Concn (mean [jlg/mlj ± SD) in serum at": 0.5 h 12 h Cefoxitin 62.0 ± Cefotetan 66.3 ± Cefmetazole 60.4 ± ± 1.2 a Daily dose, 600 mg/kg of body weight. b Time after administration of drug.
3 VOL. 37, 1993 THERAPY OF B. FRAGILIS GROUP ABSCESSES 1533 TABLE 3. Effects of antimicrobial agents on i.a. infection caused by E. coli (NMRI 8), B. fragilis (NMRI 32), and B. thetaiotaomicron (NMRI 54) No. (%) of mice Log1o CFU of bacteria recovered/mouse (no. of mice infected) Dead With abscesses/total surviving E. coli B. fragilis B. thetaiotaomicron None (control) 14 (47) 16/16 (100) 8.7 ± 0.4 (16) 9.0 ± 0.5 (15) 8.6 t 0.4 (13) Starting 1 h before inoculation Cefoxitin 5 (17) 5/25 (20) (5) 4.2 ± 0.3 (4) (4) Cefotetan 0 (0) 4/30 (13) 2.3 ± 0.2 (2) 3.5 (1) 4.6 ± 0.6 (3) Cefmetazole 0 (0) 5/30 (17) 2.8 ± 0.4 (3) (2) 4.2 ± 0.8 (4) Starting 8 h after inoculation Cefoxitin 6 (20) 2/24 (8) 3.9 ± 0.4 (2) 4.0 (1) 3.8.(1) Cefotetan 3 (10) 25/27 (93) 4.8 ± 0.5 (4) 3.5 ± 0.2 (2) 8.2 ± 0.6 (24) Cefmetazole 2 (7) 27/28 (96) 4.5 ± 0.4 (3) 2.8 ± 0.4 (2) 8.0 ± 0.5 (26) a Thirty mice were included in each group. log to 9.0 (Table 4). A significant reduction in the number of in vitro-susceptible and -resistant organisms was noted in all instances when therapy was started 1 h before inoculation. However, although not statistically significant, for susceptible isolates the reduction was about 10 times larger in the mice that received earlier (prophylactic) therapy. In contrast, a correlation between in vitro and in vivo efficacies was noted when therapy was started 8 h after inoculation. While cefoxitin was effective against all isolates, cefotetan did not reduce the number of S. aureus or B. thetaiotaomicron organisms, and cefmetazole failed to reduce the number of B. thetaiotaomicron organisms. (ii) Abscesses caused by two organisms. The number of each organism in mixed infection in saline-treated mice was significantly (P < 0.05) higher in all instances than when the organisms were inoculated alone and varied from log1o 10.2 Effect of cephalosporin therapy on the decrease in number of organisms in s.c. abscesses induced by B. fragilis, B. thetaiotaomicron, E. coli, and S. aureus" Reduction in no. of organisms/abscess (log1o CFU + SD) Infection typeb Therapy started 1 h before inoculation Therapy started 8 h after inoculation TABLE 4. Cefoxitin Cefotetan Cefmetazole Cefoxitin Cefotetan Cefmetazole Single organism B. fragilis (8.6 ± 0.8) 5.1 ± ± ± ± ± ± 0.6 B. thetaiotaomicron (9.0 ± 0.7) 4.8 ± ± ± ± _ 0.4" 0.7 _ 0.4d E. coli (8.5 ± 0.6) 5.4 ± ± ± ± ± ± 0.7 S. aureus (8.8 ± 0.9) 3.2 ± ± ± 0.5d 2.0 ± ± ± 0.6c Two organisms B. fragilis (10.5 ± 0.5) 6.5 ± ± ± ± ± ± 0.4 E. coli (10.8 ± 0.6) 5.3 ± ± ± ± ± ± 0.2 B. thetaiotaomicron (10.2 ± 0.7) 5.9 ± ± ± ± ± 0.4" 2.2 ± 0.5d E. coli (11.3 ± 0.7) 6.0 ± ± d 5.1 ± ± 1.0" 5.6 ± 0.6 B. fragilis ( ) 5.8 ± ± ± ± ± ± 0.7d S. aureus (10.3 ± 0.6) 5.2 ± ± ± 0.9c 4.8 ± ± 0.4" 7.4 ± 0.8" B. thetaiotaomicron (11.0 ± 0.8) 6.3 ± ± ± 1.0" 5.4 ± ± ± 0.4 S. aureus (10.5 ± 0.9) 4.8 ± ± l.c 4.6 _ ± ± 0.6c Three organisms B. fragilis (10.2 ± 7) 7.2 ± ± ± ± ± 0.9 B thetaiotaomicron (10.6 ± 0.6) 6.8 ± ± ± ± ± 0.5" 0.8 ± 0.4" E. coli (11.6 ± 1.3) 5.5 ± ± 0.3" 7.0 ± ± ± 1.2" " B. fragilis (10.9 ± 0.6) 7.7 ± ± ± ± ± ± 1.3 B. thetaiotaomicron (11.2 ± 0.7) 6.4 ± ± ± ± ± 0.3" 2.0 ± 0.7d S. aureus (11.8 ± 0.8) 5.2 ± ± ± 0.9" 4.8 ± ± ± 1.2" a Each treatment group contained 20 mice. b Log10 CFU + standard deviations of organisms in saline-treated mice are given in parentheses. c Significant difference compared with reduction by cefoxitin or cefotetan. d Significant difference compared with reduction by cefoxitin.
4 1534 BROOK to Similar to results for abscesses caused by a single bacterial species, a significant reduction in the numbers of all in vitro-susceptible and -resistant isolates was observed when therapy was started early but not when it was delayed. In delayed therapy, cefmetazole was highly effective against S. aureus compared with the other two cephalosporins (P < 0.05). (iii) Abscesses caused by three organisms. For abscesses caused by three organisms, as for infection caused by one or two organisms, all three cephalosporins were independently effective in vivo, in accordance with their in vitro activities, and significantly reduced the numbers of all organisms when therapy was started prior to their inoculation. However, when therapy was started 8 h after inoculation, the reduction of susceptible bacteria was generally decreased by 1 log. While cefoxitin reduced the numbers of all organisms in infections caused by either E. coli or S. aureus with both B. fragilis group isolates, cefotetan and cefmetazole did not reduce the number of B. thetaiotaomicron organisms. Cefmetazole was, however, the most effective agent against the S. aureus component of the infection. DISCUSSION This study illustrates the efficacy of all the cephalosporins tested-cefoxitin, cefotetan, and cefmetazole-in the prevention of polymicrobial infection due to E. coli or S. aureus with B. fragilis and/or B. thetaiotaomicron when therapy is started 1 h prior to inoculation of the infectious organisms. This study illustrates the discrepancies between in vitro and in vivo efficacies of cefotetan and cefmetazole when these agents are given prior to inoculation of bacteria. They were active in vitro against B. fragilis but not against B. thetaiotaomicron. However, when administered prior to bacterial challenge, they were effective in reducing the instances of sepsis and the number of animals with abscesses. This discrepancy between in vitro susceptibility and in vivo efficacy may be due to an inoculum effect in which early antibiotic administration can suppress the relatively small number of bacteria present in the infection site (6). However, when antimicrobial therapy is given 8 h later, after the bacteria have had time to increase in number, their resistance to certain cephalosporins is more apparent. These data highlight the importance of prophylactic antibiotic therapy that is given prior to the occurrence of infection. The present report also confirms the previously observed synergistic relationship between aerobic and anaerobic bacteria (9). Interruption of this synergistic relationship at an earlier stage of the infection by an antimicrobial agent that is effective against only one or two components of the mixed infection may be sufficient to abort the progression of the mixed infection (3). This may be another factor that contributes to the efficacy of cefotetan and cefmetazole against in vitro-resistant organisms when these antibiotics are administered at an earlier stage of the infection. These in vivo data support previous clinical experience of the use of cefotetan (2, 21) and cefmetazole (20) in surgical prophylaxis and our retrospective clinical observations in which we found no difference in the prophylactic uses of cefotetan and cefoxitin for colorectal surgery in over 400 patients at our hospital (6a). Cefotetan and cefmetazole are relatively new cephalosporins with longer half-lives (cefotetan, 3.3 h; cefmetazole, 1.2 h) than cefoxitin (0.68 to 0.98 h). Their prolonged half-lives allow their administration once or twice a day, ANTIMICROB. AGENTS CHEMOTHER. compared with three or four times a day for cefoxitin. They have generally lower MICs against members of the family Enterobacteraceae than does cefoxitin (4), and cefmetazole has improved activity against S. aureus (15). Although cefotetan and cefmetazole are as effective as cefoxitin against B. fragilis, they are less active against the other members of the B. fragilis group (1, 12-14, 16). This study illustrates the efficacy of prophylactic use of cefotetan and cefmetazole in the prevention of infection. It also highlights the efficacy of cefmetazole in the prevention and therapy of infection caused by S. aureus and B. fragilis group organisms. Further studies to investigate the clinical significance of these observations are warranted. ACKNOWLEDGMENTS I thank J. E. Perry for technical assistance and C. H. Dorsey for electron microscopy. REFERENCES 1. Aldridge, K E., C. V. Sanders, A. Janney, S. Faro, and R. L. Marier Comparison of the activities of penicillin G and new 1-lactam antibiotics against clinical isolates of Bacteroides species. Antimicrob. Agents Chemother. 26: Barry, A. L Criteria for in vitro susceptibility testing of cefotetan. Correlation with clinical and bacteriologic responses. Am. J. Surg. 155: Brook, I Enhancement of growth of aerobic and facultative bacteria in mixed infections with Bacteroides species. Infect. Immun. 50: Brook, I In vitro susceptibility and in vivo efficacy of antimicrobials in the treatment of Bacteroides fragilis-escherichia coli infection in mice. J. Infect. Dis. 160: Brook, I Pediatric anaerobic infection: diagnosis and management, 2nd ed. C.V. Mosby, St. Louis. 6. Brook, I The inoculum effect. Rev. Infect. Dis. 11: a.Brook, I., et al. Unpublished data. 7. Brook, I., J. C. Coolbaugh, and R. I. Walker Pathogenicity of piliated and encapsulated Bacteroides fragilis. Eur. J. Clin. Microbiol. 3: Brook, I., and E. F. Frazier Aerobic and anaerobic bacteriology of wounds and cutaneous abscesses. Arch. Surg. 125: Brook, I., V. Hunter, and R. I. Walker Synergistic effect of Bacteroides, Clostridium, Fusobacterium, anaerobic cocci, and aerobic bacteria on mortality and induction of subcutaneous abscesses in mice. J. Infect. Dis. 149: Brook, I., and R. I. Walker Infectivity of organisms recovered from polymicrobial abscesses. Infect. Immun. 42: Cato, E. P., and J. L. Johnson Reinstatement of species rank for Bacteroides fragilis, B. ovatus, B. distasonis, B. thetaiotaomicron, and B. vulgatus: designation of neotype strains for Bacteroides fragilis (Veillon and Zuber) Castellani and Chalmers and Bacteroides thetaiotaomicron (Distaso) Castellani and Chalmers. Int. J. Syst. Bacteriol. 26: Cornick, N. A., G. J. Cuchural, D. R. Snydman, N. V. Jacobus, P. lannini, G. Hill, T. Cleary, J. P. O'Keefe, C. Pierson, and S. M. Flnegold The antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States. J. Antimicrob. Chemother. 25: Cormick, N. A., N. V. Jacobus, and S. L. Gorbach Activity of cefmetazole against anaerobic bacteria. Antimicrob. Agents Chemother. 31: File, T. M., Jr., R. B. Thompson, Jr., J. S. Tan, S. J. Salstrom, G. A. Jacobs, L. Johnson, and L. Tan In vitro susceptibility of Bacteroides firagilis group in community hospitals. Diagn. Microbiol. Infect. Dis. 5: Finegold, S. M Anaerobic bacteria in human disease. Academic Press, New York. 15a.Institute of Laboratory Animal Resources Guide for the
5 VOL. 37, 1993 care and use of laboratory animals. U.S. Department of Health, Education, and Welfare publication no. (NIH) Institute of Laboratory Animal Resources, National Research Council, Bethesda, Md. 16. Jones, R. N Review of the in vitro spectrum and characteristics of cefmetazole (CS-1170). J. Antimicrob. Chemother. 23(Suppl. D): Kasper, D. L The polysaccharide capsule of Bacteroides fragilis subspecies fragilis: immunochemical and morphologic definition. J. Infect. Dis. 133: Lennette, E. H., A. Balows, W. J. Hausler, Jr., and H. G. Shadomy (ed.) Manual of clinical microbiology, 4th ed. THERAPY OF B. FRAGILIS GROUP ABSCESSES 1535 American Society for Microbiology, Washington, D.C. 19. Neu, H. C The new beta-lactamase-stable cephalosporins. Ann. Intern. Med. 97: Plouffe, J. F Cefmetazole versus cefoxitin in prevention of infections after abdominal surgery. J. Antimicrob. Chemother. 23(Suppl. D): Sheikh, W., and D. G. Bobey Lack of predictability of cefotetan in vitro susceptibility tests against clinical and bacteriologic efficacies. Diagn. Microbiol. Infect. Dis. 15: Sutter, V. L., D. M. Citron, M. A. C. Edelstein, and S. M. Finegold Wadsworth anaerobic bacteriology manual, 4th ed. Star Publishing, Belmont, Calif.
Use of Semisolid Agar for Initiation of Pure Bacteroides fragilis Infection in Mice
INFECTION AND IMMUNITY, Sept. 1976, p. 721-725 Copyright C 1976 American Society for Microbiology Vol. 14, No. 3 Printed in U.S.A. Use of Semisolid Agar for Initiation of Pure Bacteroides fragilis Infection
More informationSpiral Gradient Endpoint Method Compared to Standard Agar Dilution for Susceptibility Testing of Anaerobic Gram-Negative Bacilli
JOURNAL OF CLINICAL MICROBIOLOGY, May 1991, p. 975-979 0095-1137/91/050975-05$02.00/0 Copyright 1991, American Society for Microbiology Vol. 29, No. 5 Spiral Gradient Endpoint Method Compared to Standard
More informationRapid Identification of Bacteroides fragilis with Bile and
JOURNAL OF CuNICAL MICROBIOLOGY, Apr. 1977, p. 439-443 Copyright C 1977 American Society for Microbiology Vol. 5, No. 4 Printed in U.S.A. Rapid Identification of Bacteroides fragilis with Bile and Antibiotic
More informationRapid Identification of Bacteroides fragilis with Bile and
JOURNAL OF CuNICAL MICROBIOLOGY, Apr. 1977, p. 439-443 Copyright C 1977 American Society for Microbiology Vol. 5, No. 4 Printed in U.S.A. Rapid Identification of Bacteroides fragilis with Bile and Antibiotic
More informationMeropenem: in-vitro activity and kinetics of activity against organisms of the Bacteroides fragilis group
Journal of Antimicrobial Chemotherapy (99) 7, 599-606 Meropenem: in-vitro activity and kinetics of activity against organisms of the Bacteroides fragilis group J. A. Garcia-Rodriguez, J. E. Garcia Sanchez,
More informationPolysaccharide-mediated Protection Against Abscess Formation in
Polysaccharide-mediated Protection Against Formation in Experimental Intra-Abdominal Sepsis Arthur 0. Tzianabos,* Dennis L. Kasper,*" Ronald L. Cisneros,* Roger S. Smith,* and Andrew B. Onderdonk* Channing
More informationAnimal models for the study of. staphylococci. Niels Frimodt Møller Professor, MD DMSc Dept. of Clinical Microbiology Hvidovre Hospital Denmark
Animal models for the study of antibiotic PKPD against staphylococci Niels Frimodt Møller Professor, MD DMSc Dept. of Clinical Microbiology Hvidovre Hospital Denmark Animal models for antibiotic acitivity
More informationRate of Penicillin Killing of Staphylococcus aureus and
JOURNAL OF CLINICAL MICROBIOLOGY, Feb. 1982, p. 27-274 95-1137/82/227-5$2./ Vol. 15, No. 2 Rate of Penicillin Killing of Staphylococcus aureus and Autobac 1 Susceptibility Test Results JO-ANN HARRIS' AND
More informationABC. Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved Guideline. Volume 19 Number 18
M26-A ISBN 1-56238-384-1 September 1999 ISSN 0273-3099 Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved Guideline Volume 19 Number 18 Arthur L. Barry, Ph.D. William A. Craig,
More informationSusceptibility Tests
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 1982, p. 213-217 Vol. 16, No. 2 0095-1137/82/080213-05$02.00/0 In Vitro Studies with Cefotaxime: Disk Diffusion Susceptibility Tests SMITH SHADOMY* AND EDWARD L.
More informationEvaluation of the E Test for Susceptibility Testing
JOURNAL OF CLINICAL MICROBIOLOGY, OCt. 1991, p. 2197-2203 0095-1137/91/102197-07$02.00/0 Copyright ) 1991, American Society for Microbiology Vol. 29, No. 10 Evaluation of the E Test for Susceptibility
More informationSulfamethoxazole and Trimethoprim: Correlation with a Disk
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 1981, p. 731-735 Vol. 20, No. 6 0066-4804/81/120731-05$02.00/0 Agar Dilution Susceptibility of Bacteroides spp. to Sulfamethoxazole and Trimethoprim: Correlation
More informationEffect of Diuresis on Staphylococcus aureus Kidney
INFECTION AND IMMUNITY, Dec. 1971, p. 74-746 Copyright 1971 American Society for Microbiology Vol. 4, No. 6 Printed in U.S.A. Effect of Diuresis on Staphylococcus aureus Kidney Infections in Mice DOLORES
More informationMicrobiology for Oral and Topical Products - The basics Scott Colbourne Business Manager NSW ALS Food & Pharmaceutical
Microbiology for Oral and Topical Products - The basics Scott Colbourne Business Manager NSW ALS Food & Pharmaceutical RIGHT S O L U T I O N S RIGHT PARTNER Contents TGO 77 - Introduction Tests Performed
More informationFactors Influencing Detection of Tolerance in Staphylococcus aureus
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 1982, p. 364-368 Vol. 22, No. 3 0066-4804/82/090364-0$02.00/0 Copyright 1982, American Society for Microbiology Factors Influencing Detection of Tolerance in
More informationSKIN INFECTION OF RABBITS WITH HEMOLYTIC STREP- TOCOCCI ISOLATED FROM A PATIENT WITH ERYSIPELAS.
SKIN INFECTION OF RABBITS WITH HEMOLYTIC STREP- TOCOCCI ISOLATED FROM A PATIENT WITH ERYSIPELAS. I. METHOD OF DEMONSTRATING PROTECTIVE ACTION OF IMMUNE SERA. BY THOMAS M. RIVERS, M.D. (From the Hospital
More informationBacterial load was measured using the method described previously (1). The necrotic tissue
Supplemental Methods Bacterial Load Quantification Bacterial load was measured using the method described previously (1). The necrotic tissue was excised, and then 2 mm (width) 2 mm (length) 1-5 mm (depth)
More informationReport on New Patented Drugs - Invanz
Report on New Patented Drugs - Invanz October 2006 Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drugs by Board Staff, for purposes of applying the PMPRB
More informationActivity of meropenem and other antimicrobial agents against uncommon Gram-negative organisms
Journal of Antimicrobial Chemotherapy (993) 3, 33-37 Activity of and other antimicrobial agents against uncommon Gram-negative organisms Richard B. Clark and Suzanne E. Joyce Department of Pathology, Crozer-Chester
More informationBiofilm Protocol Optimization For Pseudomonas aeruginosa. Introduction. Materials and Methods. Culture Media, Incubation Time, and Biofilm Measurement
Biofilm Protocol Optimization For Pseudomonas aeruginosa Culture Media, Incubation Time, and Biofilm Measurement Introduction In addition to the conventional arsenal of antibiotic resistance mechanisms
More informationAdherence of Bacteroides fragilis In Vivo
INFECTION AND IMMUNITY, March 1978, p. 1083-1087 0019-9567/78/0019-1083$02.00/0 Copyright 1978 American Society for Microbiology Adherence of Bacteroides fragilis In Vivo Vol. 19, No. 3 Printed in U.S.A.
More informationA clinically orientated procedure for the workup of anaerobic bacteria in the era of MALDI-TOF: feasible or fiction?
A clinically orientated procedure for the workup of anaerobic bacteria in the era of MALDI-TOF: feasible or fiction? Author: apr. Bart Peeters Supervisor: dr. Reinoud Cartuyvels Date: 19/05/2015 Content
More informationBD Schaedler Agar/Schaedler KV Agar with 5% Sheep Blood (Biplate)
PA-254476.06-1 - INSTRUCTIONS FOR USE READY-TO-USE PLATED MEDIA PA-254476.06 Rev.: Aug 2016 INTENDED USE is used for the nonselective isolation of anaerobes and for the selective isolation of Gram-negative
More informationPostantibiotic and Sub-MIC Effects of Azithromycin and Isepamicin against Staphylococcus aureus and Escherichia coli
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 1998, p. 414 418 Vol. 42, No. 2 0066-4804/98/$04.00 0 Copyright 1998, American Society for Microbiology Postantibiotic and Sub-MIC Effects of and against Staphylococcus
More informationThe Cat s Out of the Bag: Microbiological Investigations of Acute Transfusion Reactions.
The Cat s Out of the Bag: Microbiological Investigations of Acute Transfusion Reactions. Philippe Lagacé-Wiens, MD FRCPC, DTM&H plagacewiens@sharedhealthmb.ca COI declaration I have no conflicts, real
More informationComparison of the In Vitro Bactericidal Activity of Human
INFECTION ND IMMUNITY, Sept. 1976, p. 843-847 Copyright 1976 merican Society for Microbiology Vol. 14, No. 3 Printed in U.S.. Comparison of the In Vitro Bactericidal ctivity of Human Serum and Leukocytes
More informationPharmacodynamics of Ampicillin-Sulbactam in an In Vitro Infection Model against Escherichia coli Strains with Various Levels of Resistance
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 1998, p. 231 235 Vol. 42, No. 2 0066-4804/98/$04.00 0 Copyright 1998, American Society for Microbiology Pharmacodynamics of Ampicillin-Sulbactam in an In Vitro
More informationJohan W Mouton Canisius-Wilhelmina Hospital Nijmegen, The Netherlands
Can pk/pd replace clinical trials? Johan W Mouton Canisius-Wilhelmina Hospital Nijmegen, The Netherlands The Traditional Approach Phase Participants Research questions Number Characteristics I 10-50 Usually
More informationComparison of Methods for Recovery of Clostridium difficile
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 1983, p. 348-352 0095-1137/83/080348-05$02.00/0 Copyright 0 1983, American Society for Microbiology Vol. 18, No. 2 Comparison of Methods for Recovery of Clostridium
More informationobtained from the infected and treated tissues, Fleming's2 technic of hemolytic streptococcus B. Immediately following the infection, 1.0 ml.
THE SENSITIVITY OF STREPTOCOCCI TO PENICILLIN G AFTER EXPOSURE TO THE ANTIBIOTIC IN VIVO* E. GRUNBERG, C. UNGER, AND D. ELDRIDGE Previous investigations by Grunberg, Schnitzer, and Unger3 on the topical
More information01/08/2018. Control of Microbial Growth. Methods. Terminology. Disinfectants and Antiseptics. Three approaches. Cleaning. Chemical.
Control of Microbial Growth Disinfectants and Antiseptics 1 Methods 2 Three approaches Chemical Disinfectants and antiseptics Physical Heat Ultraviolet Irradiations Mechanical elimination Cleaning Filtration
More information10/2/2016. Control of Microbial Growth. Method. Terminology. Disinfectants and Antiseptics
Control of Microbial Growth Disinfectants and Antiseptics 1 Method Three approaches for the control of microbial growth Chemical Disinfectants and antiseptics Physical Heat Ultraviolet Irradiations Mechanical
More informationStudy Title Antibacterial Activity and Efficacy of KHG FiteBac Technology Test Substance Using a Suspension Time-Kill Procedure
Study Title Antibacterial Activity and Efficacy of KHG FiteBac Technology Test Substance Using a Suspension Time-Kill Procedure Test Method ASTM International Method E2315 Assessment of Antimicrobial Activity
More informationANAEROBIC DENTAL INFECTIONS AND ADVANCE LABORATORY DIAGNOSIS: A MINI REVIEW
Review Article Biswajit Batabyal,, 2012; Volume 1(5):533-538 ISSN: 2277-8713 ANAEROBIC DENTAL INFECTIONS AND ADVANCE LABORATORY DIAGNOSIS: A MINI REVIEW BISWAJIT BATABYAL 1,SUKANTA CHAKRABORTY 2, SHIBENDU
More informationPostantibiotic effect of roxithromycin, erytfaromycin, and clindamycin against selected Gram-positive bacteria and Haemophilus influenzae
Journal of Antimicrobial Chemotherapy (1987) 20, Suppl. B, 39-46 Postantibiotic effect of roxithromycin, erytfaromycin, and clindamycin against selected Gram-positive bacteria and Haemophilus influenzae
More informationPASSIVE PROTECTION BY HUMAN SERUM IN MICE INFECTED WITH ENCAPSULATED STAPHYLOCOCCUS A UREUS
PASSIVE PROTECTION BY HUMAN SERUM IN MICE INFECTED WITH ENCAPSULATED STAPHYLOCOCCUS A UREUS K. YOSHIDA, Y. ICHIMAN, S. NARIKAWA, M. TAKAHASHI, E. KONO* AND C. L. SAN CLEMENTE? Department of Microbiology
More informationTest Method for the Continuous Reduction of Bacterial Contamination on Copper Alloy Surfaces
Test Method for the Continuous Reduction of Bacterial Contamination on Copper Alloy Surfaces Test Organisms: Staphylococcus aureus (ATCC 6538) Enterobacter aerogenes (ATCC 13048) Pseudomonas aeruginosa
More informationDETERMINATION OF THE ID50 VALUES OF ANTIBACTERIAL AGENTS IN AGAR. TAKAKO KATO, SATONORI KURASHIGE, Y. A. CHABBERT* and SUSUMU MITSUHASHI
1299 DETERMINATION OF THE ID50 VALUES OF ANTIBACTERIAL AGENTS IN AGAR TAKAKO KATO, SATONORI KURASHIGE, Y. A. CHABBERT* and SUSUMU MITSUHASHI Department of Microbiology, School of Medicine, Gunma University,
More informationINFLUENCE OF GUINEA PIG PLASMA FACTORS ON PHAGOCYTOSIS
INFLUENCE OF GUINEA PIG PLASMA FACTORS ON PHAGOCYTOSIS OF PASTEURELLA PESTIS II. PLASMA FROM PLAGUE-INFECTED GUINEA PIGS W. G. STANZIALE1 AND J. D. WHITE U. S. Army Chemical Corps Biological Laboratories,
More informationPhotodynamic inactivation of multidrug resistant pathogens in Hong Kong
RESEARCH FUND FOR THE CONTROL OF INFECTIOUS DISEASES CMN Yow 邱李妙顏 K Fung 馮秀珍 KC Wong 黃建忠 Key Messages 1. Photodynamic therapy could be an alternative treatment for highly prevalent local antibiotic-resistant
More informationPharmacokinetics as applied to in vitro and animal models
Pharmacokinetics as applied to in vitro and animal models Michael R. Jacobs, MD, PhD Case Western Reserve University University Hospitals of Cleveland Cleveland, OH Topics In vitro pharmacodynamic models
More informationSetting Clinical Breakpoints/ECOFFS
23 rd August 2016 Setting Clinical Breakpoints/ECOFFS Robin A Howe Antimicrobial use in Primary Care An E. coli is grown from blood cultures Cefuroxime MIC 2mg/L Zone around CXM 30ug disc 27mm Is it sensitive?
More informationFURTHER OBSERVATIONS ON THE AGGLUTINATION OF BACTERIA IN VIVO.
FURTHER OBSERVATIONS ON THE AGGLUTINATION OF BACTERIA IN VIVO. BY CARROLL G. BULL, M.D. (From the Laboratories of The Rockefeller Institute for Medical Research.) PLATE 7. (Received for publication, April
More informationMulticenter Evaluation of Four Methods of Yeast Inoculum Preparation
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 1988, p. 1437-1441 0095-1137/88/081437-05$02.00/0 Copyright C 1988, American Society for Microbiology Vol. 26, No. 8 Multicenter Evaluation of Four Methods of Yeast
More informationStability of Antibiotics and Chemotherapeutics in
APPUED MICROBIOLOGY, Sept. 1970, p. 447-451 Copyright 1970 American Society for Microbiology Vol. 20, No. 3 Printed in U.S.A. Stability of Antibiotics and Chemotherapeutics in Agar Plates KENNETH J. RYAN,
More informationMicrobiology sheet (6)
Microbiology sheet (6) Made by marah marahleh corrected by : abd. Salman DATE :9/10/2016 Microbial growth / control of microbial growth 1 The method of counting bacteria is divided into: 1) direct 2) indirect
More informationCHAPTER 24. Immunology
CHAPTER 24 Diagnostic i Microbiology and Immunology Growth-Dependent Diagnostic Methods Isolation of Pathogens from Clinical Specimens Proper sampling and culture of a suspected pathogen is the most reliable
More informationEXPERIMENTAL BLASTOMYCOSIS IN MICE' JOSEPH M. HITCH, M.D. Wim THE TECHNICAL ASSISTANCE OF JANE S. SHARP, M.S.
EXPERIMENTAL BLASTOMYCOSIS IN MICE' JOSEPH M. HITCH, M.D. Raleigh, N. C.; Instructor in Dermatology and Syphilology, Duke University School of Medicine Wim THE TECHNICAL ASSISTANCE OF JANE S. SHARP, M.S.
More informationIN THIS SECTION MICROBIOLOGY TESTING EXPERT SOLUTIONS FOR PRODUCT DEVELOPMENT. Bacterial Endotoxin (LAL) Testing
EXPERT SOLUTIONS FOR PRODUCT DEVELOPMENT IN THIS SECTION MICROBIOLOGY TESTING Microbial assays involve a variety of tests, from the determination of the numbers and types of organisms naturally present
More information2016 Europe-Nordic-US Symposium New Frontiers in Antibacterial Resistance Research. Pharmacological Approaches to Address AR
2016 Europe-Nordic-US Symposium New Frontiers in Antibacterial Resistance Research Pharmacological Approaches to Address AR G.L. Drusano, M.D. Professor and Director Institute for Therapeutic Innovation
More informationMicrobicidal Properties of a Silver-Containing Hydrofiber Dressing Against a Variety of Burn Wound Pathogens
Microbicidal Properties of a Silver-Containing Hydrofiber Dressing Against a Variety of Burn Wound Pathogens P. G. Bowler, MPhil, S. A. Jones, BSc, M. Walker, PhD, D. Parsons, PhD Partial-thickness burns
More informationMethodology for Recovery of Chemically Treated Staphylococcus aureus with Neutralizing Medium
APPLIED AND ENVIRONMENTAL MICROBIOLOGY, May 1983, p. 33-37 99-22/83/533-5$2./ Copyright 1983, American Society for Microbiology Vol. 5, No. 5 Methodology for Recovery of Chemically Treated Staphylococcus
More informationMAb. The production and characterization of the MAb. have been described earlier (12, 13). Briefly, B. fragilis
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 1988, p. 448-452 0095-1137/88/030448-05$02.00/0 Copyright «D 1988, American Society for Microbiology Vol. 26, No. 3 Detection of Bacteroides fragilis, Bacteroides
More informationAntimicrobial activity (in vitro) of polysaccharide gel from durian fruit-hulls
ORIGINAL ARTICLE Antimicrobial activity (in vitro) of polysaccharide gel from durian fruit-hulls Vimolmas Lipipun 1, Nantawan Nantawanit 2 and Sunanta Pongsamart 3 Abstract Lipipun, V., Nantawanit, N.
More informationStudy Title Antimicrobial Activity and Efficacy of Seal Shield's Electroclave. Test Method Custom Device Study. Study Identification Number NG7233
Study Title Antimicrobial Activity and Efficacy of Seal Shield's Electroclave Test Method Custom Device Study Study Identification Number NG7233 Study Sponsor Christian Davis Seal Shield 3105 Riverside
More informationAntibiotic Susceptibility of Anaerobic Bacteria
AwNrIcRoBuL AIGENTS AND CHUMOT R"PY, Mar. 1973, p. 35O-356 Copyright 1973 American Society for Microbiology Vol. S, No. 3 Prind in U.S.A. Modified Broth-Disk Method for Testing the Antibiotic Susceptibility
More informationAntibiotic Susceptibility of Anaerobic Bacteria
AwNrIcRoBuL AIGENTS AND CHUMOT R"PY, Mar. 1973, p. 35O-356 Copyright 1973 American Society for Microbiology Vol. S, No. 3 Prind in U.S.A. Modified Broth-Disk Method for Testing the Antibiotic Susceptibility
More informationISOLATION AND CHARACTERISATION OF BACTERIA FROM ABSCESSES IN THE SUBCUTIS OF CATS
ISOLATION AND CHARACTERISATION OF BACTERIA FROM ABSCESSES IN THE SUBCUTIS OF CATS DARIA N. LOVE*, R. F. JONES*, MARILYN BAILEY* AND R. s. JOHNSON *Department of Veterinary Pathology, University of Sydney,
More informationVerification of Disk Diffusion Tests
Verification of Disk Diffusion Tests Objectives 1. Describe disk diffusion tests 2. Describe process of FDA clearance of susceptibility tests 3. Discuss CLIA requirements for laboratory verification of
More information6/28/2016. Control of Microbial Growth. Method. Terminology. Disinfectants and Antiseptics
Control of Microbial Growth Disinfectants and Antiseptics 1 Method Three approaches for the control of microbial growth Chemical Disinfectants and antiseptics Physical Heat Ultraviolet Irradiations Mechanical
More informationINTRODUCTION Contaminated serial dilution countable plates
INTRODUCTION In recent days, the foods that we consume are usually pre-processed in a facility removed from our home, cities, countries, and even continents. It is now more than ever important to be aware
More informationComparison of the speed of kill of pathogenic bacteria using ACTICOAT and AQUACEL Ag analysed using Confocal Laser Scanning Microscopy
Smith & Nephew Wound Management Data on file report - 0505004 May 2005 Comparison of the speed of kill of pathogenic bacteria using ACTICOAT and AQUACEL Ag analysed using Confocal Laser Scanning Microscopy
More informationgroup C /8-hemolytic streptococci, a-hemolytic been exposed to penicillin, on the removal of the drug there follows a variable recovery period during
THE RECOVERY OF BACTERIA FROM THE TOXIC EFFECTS OF PENICILLIN1 By HARRY EAGLE (From the Section on Experimental Therapeutics, National Institutes of Health, U. S. Public Health Service, Bethesda 14, Maryland)
More informationPractical Aerobic Membrane Filtration Blood Culture
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 1975, p. 3-36 Copyright ( 1975 American Society for Microbiology Vol. 1, No. 1 Printed in U.S.A. Practical Aerobic Membrane Filtration Blood Culture Technique: Development
More informationOptimized Pathogen Detection with 30- Compared to 20-Milliliter Blood Culture Draws
JOURNAL OF CLINICAL MICROBIOLOGY, Dec. 2011, p. 4047 4051 Vol. 49, No. 12 0095-1137/11/$12.00 doi:10.1128/jcm.01314-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Optimized
More informationINFLUENCE OF A SUB INHIBITORY CONCENTRATION OF ANTIBIOTICS ON OPSONO-PHAGOCYTIC FUNCTIONS OF KLEBSIELLA PNEUMONIAE BY HUMAN PHAGOCYTES
Influence of sub-mic of antibiotics on phagocytes 1487 INFLUENCE OF A SUB INHIBITORY CONCENTRATION OF ANTIBIOTICS ON OPSONO-PHAGOCYTIC FUNCTIONS OF KLEBSIELLA PNEUMONIAE BY HUMAN PHAGOCYTES YASUO ONO,
More information!Bio-Bag Environmental Chamber Type A
Revisions Rev From Rev To ECO # Date Appr. 1189 0703 2030-03 Notes :1. BD Cat. No. 261215 2. Blank (Sheet) Size : Length: 8.5 Width: 11 Number of Pages: 4 Number of Sheets: 1 Page Size: Length 8.5 Width
More informationTest Method for Efficacy of Copper Alloy Surfaces as a Sanitizer
Test Method for Efficacy of Copper Alloy Surfaces as a Sanitizer Test Organisms: Staphylococcus aureus (ATCC 6538) Enterobacter aerogenes (ATCC 13048) Pseudomonas aeruginosa (ATCC 15442) Methicillin Resistant
More informationEncapsulated Anaerobic Bacteria in Synergistic Infections
MICROBIOLOGICAL REVIEWS, Dec. 1986, p. 452-457 0146-0749/86/040452-06$02.00/0 Copyright C) 1986, American Society for Microbiology Vol. 50, No. 4 Encapsulated Anaerobic Bacteria in Synergistic Infections
More informationKey words: Paracetamol, antibacterial activity, chemical preservative, zone of inhibition.
In Vitro Assessment of Antibacterial Activity of lamatecara Preservatives Abstract: The objective of the current research was to evaluate the efficacy of different preservatives of paracetamol syrup against
More informationIdentification of the In Vivo Pharmacokinetics and Pharmacodynamic Drivers of Iclaprim
AAC Accepted Manuscript Posted Online 29 January 2018 Antimicrob. Agents Chemother. doi:10.1128/aac.02550-17 Copyright 2018 American Society for Microbiology. All Rights Reserved. 1 Identification of the
More informationBlood cultures. Sept 2013 A/Prof John Ferguson (nepal)
Blood cultures Sept 2013 A/Prof John Ferguson jferguson@hnehealth.nsw.gov.au www.hicsiganz.org (nepal) Clinical importance Diagnostic : Establishes or confirms the infectious aetiology Provides susceptibility
More informationEvolution of Anaerobe Susceptibility Testing in the United States
SUPPLEMENT ARTICLE Evolution of Anaerobe Susceptibility Testing in the United States David W. Hecht Infectious Diseases Division, Loyola University Medical Center, and Hines VA Hospital, Maywood, Illinois
More information2120 Lab. Week 11. Experiments 13,14,21. Kirby Bauer, TDT, Chemicals
2120 Lab Week 11 Experiments 13,14,21 Kirby Bauer, TDT, Chemicals Controlling Microorganisms Decontamination: Physical, chemical, and mechanical methods to destroy or reduce undesirable microbes in a given
More informationDr. Hala Al Daghistani. (1) They are often contiguous with a mucosal surface.
Dr. Hala Al Daghistani Anaerobic Infections - A large majority of the bacteria that make up the normal human microbiota are anaerobes. - Certain characteristics are suggestive of anaerobic infections:
More informationTransmission Electron Microscopic Study of Antibiotic Action on Klebsiella pneumoniae Biofilm
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2002, p. 2679 2683 Vol. 46, No. 8 0066-4804/02/$04.00 0 DOI: 10.1128/AAC.46.8.2679 2683.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationVerification of Gradient Diffusion Strips
Verification of Gradient Diffusion Strips Objectives 1. Describe gradient diffusion tests 2. Describe process of FDA clearance of susceptibility tests 3. Discuss CLIA requirements for laboratory verification
More informationINSTRUCTIONS FOR USE LYFO DISK KWIK-STIK KWIK-STIK PLUS. n LYFO DISK Microorganisms n KWIK-STIK Microorganisms n KWIK-STIK Plus Microorganisms
INSTRUCTIONS FOR USE n LYFO DISK Microorganisms n KWIK-STIK Microorganisms n KWIK-STIK Plus Microorganisms LYFO DISK INTENDED USE LYFO DISK, KWIK-STIK and KWIK-STIK Plus Microorganisms are lyophilized,
More informationCI-867, a New Semisynthetic Penicillin: In Vitro Studies
ANTIROBIAL AGENTS AND CHEMOTHERAPY, Dec. 19, p. 939-943 66-44//12-939/5$2./ Vol. 18, No. 6, a New Semisynthetic Penicillin: In Vitro Studies SUSANNE S. WEAVER AND GERALD P. BODEY* Department of Developmental
More informationImmobilization and Death of Bacteria by Flora Seal Microbial Sealant
International Journal of Pharmaceutical Science Invention ISSN (Online): 2319 6718, ISSN (Print): 2319 670X Volume 6 Issue 6 June 2017 PP. 45-49 Immobilization and Death of Bacteria by Flora Seal Microbial
More informationDisk Diffusion Method for Susceptibility Testing of
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 1991, p. 1604-1609 0095-1137/91/081604-06$02.00/0 Copyright 1991, American Society for Microbiology Vol. 29, No. 8 Disk Diffusion Method for Susceptibility Testing
More informationReceived 26 February 1997/Returned for modification 16 September 1997/Accepted 10 February 1998
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 1998, p. 1093 1097 Vol. 42, No. 5 0066-4804/98/$04.00 0 Copyright 1998, American Society for Microbiology Comparison of Concentrations of -Ampicillin Administered
More informationSubmitted May 16, May 23, 2014 BY:
KILL-TIME PROTOCOL Antimicrobial Activity of Five Silver-based Solutions Using Methicillin-resistant Staphylococcus aureus (MRSA) Test solutions: A, B, C, D, E Submitted May 16, 2014 May 23, 2014 BY: Richard
More informationSelenium nanoparticles and their utilization in scaffolds. Prof. RNDr. Vojtech Adam, Ph.D. Mgr. Dagmar Hegerova, Ph.D. Mendel University in Brno
Selenium nanoparticles and their utilization in scaffolds Prof. RNDr. Vojtech Adam, Ph.D. Mgr. Dagmar Hegerova, Ph.D. Mendel University in Brno 2 Content 1. Nanoparticles silver, selenium Staphylococcus
More informationClinical and Microbiological Features of Necrotizing Fasciitis
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 1995, p. 2382 2387 Vol. 33, No. 9 0095-1137/95/$04.00 0 Copyright 1995, American Society for Microbiology Clinical and Microbiological Features of Necrotizing Fasciitis
More informationToday s Topics. General Quality Control Best Practices. Practices Antimicrobial Effectiveness Testing(AET) Best Practices Environmental Isolates
Laboratory Best Practices in QC Microbiology Today s Topics General Quality Control Best Practices Growth Promotion Testing (GPT) Best Practices Antimicrobial Effectiveness Testing(AET) Best Practices
More informationSystem with BACTEC Radiometric Blood Culture Media
JOURNAL OF CLINICAL MICROBIOLOGY, Oct. 1984, p. 618-623 0095-1137/84/100618-06$02.00/0 Copyright 1984, American Society for Microbiology Vol. 20, No. 4 Clinical Laboratory Comparison of the 10-ml Isolator
More information!Difco KL Virulence Enrichment S1191JAA 2003/07
Revisions SO 0046-2 Rev From Rev To ECO # Appr. 0899 0703 2143-03 Notes: 1. BD Cat. No. 298610 2. Blank (Sheet) Size : Length: Width: Number of Pages: 4 Number of Sheets: 1 Page Size: Length 7.312 Width
More informationBD BBL TM CDC Anaerobe 5% Sheep Blood Agar
BD BBL TM CDC Anaerobe 5% Sheep Blood Agar 111-251733-N-01, April 2015 QUALITY CONTROL PROCEDURES I. INTRODUCTION CDC Anaerobe 5% Sheep Blood Agar is an enriched, nonselective culture medium particularly
More informationOptimizing Breast Pocket Irrigation: An in Vitro Study and Clinical Implications
Cosmetic Optimizing Breast Pocket Irrigation: An in Vitro Study and Clinical Implications William P. Adams, Jr., M.D., W. Chad H. Conner, B.A., Fritz E. Barton, Jr., M.D., and Rod J. Rohrich, M.D. Dallas,
More informationPK-PD TARGET SELECTION It s All About the Goal
PK-PD TARGET SELECTION It s All About the Goal Paul G. Ambrose, Pharm.D. Chair, USCAST Executive Committee President, Institute for Clinical Pharmacodynamics It s All About the Goal The choice of a rational
More informationMicrobial Synergy in Experimental Intra-Abdominal Abscess
INFMCTION AND IMMUNITY, Jan. 1976, p. 22-26 Copyright C 1976 American Society for Microbiology Vol. 13, No. 1 Printed in U.S.A. Microbial Synergy in Experimental Intra-Abdominal Abscess ANDREW B. ONDERDONK,*
More informationSuperoxide Dismutase in Bacteroides fragilis and Related Bacteroides Species
JOURNAL OF CLINICAL MICROBIOLOGY, Sept 1977, p. 280-284 Copyright 1977 American Society for Microbiology Vol. 6, No. 3 Printed in U.S.A. Superoxide Dismutase in Bacteroides fragilis and Related Bacteroides
More informationValidation and Reproducibility Assessment of Tigecycline MIC Determinations by Etest
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 2007, p. 2474 2479 Vol. 45, No. 8 0095-1137/07/$08.00 0 doi:10.1128/jcm.00089-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. Validation
More informationChapter 9 Antimicrobial Susceptibility Testing (Agar Disk Diffusion Method)
Chapter 9 Antimicrobial Susceptibility Testing (Agar Disk Diffusion Method) The disk diffusion method presented in this chapter has been carefully standardized by the National Committee for Clinical Laboratory
More informationR IC H A R D C. T IL T O N, Ph.D. A N D L IN D A L IE B E R M A N, B.S.
A n n a l s o f C l i n i c a l a n d L a b o r a t o r y S c i e n c e, Vol. 4, No. 3 Copyright 1974, Institute for Clinical Science M icrodilution Assay o f Antibiotics in Body Flu ids R IC H A R D C.
More informationTen Minute, Reagent-Free identification of Bacteria Containing Resistance Genes Using a Rapid Intrinsic Fluorescence Method
548 Ten Minute, Reagent-Free identification of Bacteria Containing Resistance Genes Using a Rapid Intrinsic Fluorescence Method R. Rozen-Sadowsky 1, A. Shinderman 1, D. Gohman 1, D. Shimonov 1, Y. Gluckman
More informationby author How to effectively report laboratory findings to clinicians (Breakpoints and Interpretation)
How to effectively report laboratory findings to clinicians (Breakpoints and Interpretation) A Vatopoulos National School of Public Health & Central Public Health Laboratory KEELPNO Antibiotic Activity
More informationASSESSMENT OF THE MICROBICIDAL ACTIVITY OF AN ACCELERATED HYDROGEN PEROXIDE- BASED FORMULATION (AHP-5) AGAINST VRE AND MRSA
Final Report submitted to Virox Technologies Inc. Oakville, Ontario ASSESSMENT OF THE MICROBICIDAL ACTIVITY OF AN ACCELERATED HYDROGEN PEROXIDE- BASED FORMULATION (AHP-5) AGAINST VRE AND MRSA Syed A. Sattar,
More informationNovel polymyxin derivatives are effective in treating experimental Escherichia coli peritoneal infection in mice
Journal of Antimicrobial Chemotherapy Advance Access published March 16, 2010 J Antimicrob Chemother doi:10.1093/jac/dkq072 Novel polymyxin derivatives are effective in treating experimental Escherichia
More information